Recent Content
- Correction: Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1
- Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma
- Bispecific antibodies in the treatment of multiple myeloma
- Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma
- Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
- ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
- Evaluating early intervention in smoldering myeloma clinical trials: a systematic review
- Navigating Multiple Myeloma Care: Balancing CAR T-Cell Therapy and Immunotherapy
- Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma
- Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma